The science
Cavadex reverses heart disease
For over 5 years Cavadex has been improving the health of people around the world by reversing heart disease and reducing arterial plaque.
How can we make these claims, and where is the science that proves it? Let us show you.
- 2013Research begins
- 5Peer-reviewed papers
- 12,000Boxes shipped by July 2024
- 6,000Orders worldwide
Groundbreaking clinical research published
Peer-reviewed evidence confirms Cavadex reverses coronary artery calcification, challenging the dogma of irreversible heart disease.
Important update: All FDA issues have been resolved and all shipments to the USA now arrive within 6–12 days.
This 5-minute video tells the story
Start here if you are new to Cavadex.
What science supports these claims?
The Cholrem development of Cavadex, year by year, from the first safety data to today.
-
2013
We know HP-B-CD is safe to use on humans because…
A human trial was conducted on twin girls suffering from Niemann-Pick disease. High dose HP-B-CD was administered via IV for over 2 years to remove cholesterol from cells.
Effects of cyclodextrin in two patients with Niemann–Pick Type C disease -
2016
We know HP-B-CD removes arterial plaque from mice because…
Scientists from Bonn University, Germany, trialed HP-B-CD on mice with atherosclerosis and discovered that HP-B-CD substantially reduced the atherosclerotic plaque.
Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming -
2019
We know HP-B-CD reduces arterial plaque in humans because…
After concluding that the science showed HP-B-CD was safe in humans and successfully reduced arterial plaque in mice, Kyle Hodgetts established Cholrem Pty Ltd and did a trial on himself using HP-B-CD to reduce his arterial plaque, resulting in substantial plaque reduction.
Peer-reviewed paper from our 2019 trial: 2-hydroxypropyl-β-cyclodextrin reduces atherosclerotic plaques in human coronary artery -
2021
We know Cavadex reduces arterial plaque and improves lipid profile and liver function because…
After the success of the first trial, Cholrem Pty Ltd developed a version of HP-B-CD, Cavadex, and Kyle did a second trial on himself, resulting in substantial lipid reduction, improved liver function and reduced arterial plaque.
Kyle consulted with Australian Professor Laurie Howes MB BS PhD FRACP FCSANZ, head of cardiovascular research at one of Australia’s largest hospitals and Professor of Pharmacology and Therapeutics at two of Australia’s leading universities, and the trial results were confirmed.
Peer-reviewed paper from our 2021 trialWe know Cavadex is absorbed into the bloodstream when administered as an enema…
Cholrem Pty Ltd developed an enema version of Cavadex for home use. The Remchol enema could supply a 25% absorption rate of Cavadex. An online store opened to commence limited sales of Remchol tubes containing Cavadex.
-
2022
Cardiologists agree with the science and start treating themselves…
USA cardiologist Dr. James Roberts MD FACC FAARFM trialed Cavadex on himself with similar results. He then went on to supply his patients with Remchol tubes.
-
2023
Patients around the world are reversing their heart disease with Cavadex…
Dr. Roberts reports all patients getting better and that Remchol-Cavadex reduced arterial plaque in his patients without any adverse side-effects. He also reported several other benefits for stroke patients and brain fog.
The medical industry starts to speak out about the benefits of Cavadex
Dr. Roberts agrees to be filmed talking about Cavadex
Patients start sharing their stories
Cholrem Pty Ltd establishes the Facebook Cavadex club, where customers using Remchol-Cavadex report their experience and results. It becomes clear that everyone benefits from Remchol-Cavadex and no adverse side-effects are reported, except some loose stools and very few reports of stomach cramps. These are concluded to come from using an enema, not from the Cavadex.
-
2024
Professor Howes puts his name and reputation behind Cavadex…
Prof. Laurie Howes writes a report about Cavadex.
Read Professor Howes’s report“It will be the greatest therapeutic advance in cardiovascular medicine since the introduction of the statins.”
The first time Professor Howes has ever been filmed supporting a product
The world is finding out that Cavadex works and saves lives
By July 2024 Cholrem has shipped a total of 12,000 boxes across 6,000 orders.
Dr. Roberts is interviewed, December 2024: all his patients are getting better
This must-see interview explains the science and how Cavadex is going to save millions of lives. Calcium scores dropping, everyone is getting better on Cavadex.
All the science: Dr. Roberts’s detailed lecture on Cavadex
- The science behind Cavadex
- Dr. Roberts talks about some of his patient outcomes and shows real results
- The safety of Cavadex
- At the end, Dr. Roberts asks you to consider helping a charity that is close to his heart
-
2025
Our third and fourth papers are published…
Third paper: taking data from multiple patients, the outcome is clear.
Cyclodextrin Therapy for Atherosclerotic Cardiovascular Disease: A Case Series on Plaque Regression and Symptomatic ImprovementFourth paper: results from 125 patients.
Symptomatic Improvement and Enhanced Quality of Life Following a 12-Week Self-Monitored Regimen of Rectally Administered Cavadex: An Observational Study -
2026
World first: calcium scores plummet with Cavadex
Our fifth peer-reviewed paper is published.
Regression of Atherosclerotic Plaque via High-Viscosity 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): A Multicenter Retrospective Case SeriesLatest: peer-reviewed evidence that Cavadex reverses established coronary artery calcification.
Regression of Established Coronary Artery Calcification via a Specialized High-Viscosity Rectal Formulation of Cavadex: A Multi-Center Longitudinal Analysis
Published research
Every paper and report, in one place. Click any card to read it.
Cavadex results explained by AI
What people report, and why
A clear breakdown of how Cavadex works: from rapid symptom relief, to the timeline for plaque reduction, to why many users report sharper memory. This AI breakdown covers the immediate changes people notice in the first month, when actual plaque reduction appears, and the science behind the changes.
What people report in the first 4 weeks
Here is what users commonly experience early on, and why it happens. Click a question to open it.
Why is my angina going away?
The rapid relief from angina is a functional victory, not a structural one. Cavadex doesn’t need to dissolve the entire solid plaque mass in two weeks to end angina. It works by dissolving superficial cholesterol crystals that trigger arterial spasms, freeing eNOS from lipid rafts to restore instant nitric oxide vasodilation, and improving red blood cell flexibility, balancing the heart’s oxygen supply-and-demand loop almost immediately.
Why does my eyesight seem to be improving?
Vision improvements reflect optimised ocular mechanics. Cavadex restores retinal capillary blood flow by reversing endothelial dysfunction, liquefies microcirculation by allowing rigid red blood cells to flex through eye capillaries, and stabilises the blood-retinal barrier to reduce the microscopic fluid accumulation that causes visual blur.
Why do I have more energy?
The surge in energy signals your biology returning to natural efficiency. Cavadex unblocks mitochondria to produce more ATP, reduces the workload on your heart by lowering systemic vascular resistance, and shuts down the chronic inflammatory cytokine storm responsible for neurological brain fog and lethargy.
Why does my skin look so good?
Skin improvements are the logical result of clean, highly functional micro-vessels and reprogrammed dermal macrophages. By activating LXR to suppress tissue-destroying cytokines, Cavadex calms chronic skin inflammation and protects the underlying collagen matrix from premature degradation.
Why don’t my feet ache anymore?
Aching stops because Cavadex opens new microvessels to end oxygen starvation, dilates existing vessels via nitric oxide, disassembles the lipid rafts holding pain receptors active on sensory nerves, and dissolves microscopic crystal deposits in the joints of the lower extremities.
Why is my erectile dysfunction improving?
Erectile function improves because Cavadex addresses the root physical mechanics of ED. It frees the eNOS enzyme to dramatically increase nitric oxide production, clears the tiny 1–2 mm penile arteries that are highly vulnerable to lipid bottlenecks, and increases blood flow velocity by making red blood cells flexible enough to fill the microvasculature.
When can I expect my plaque to start reducing?
Stabilisation & softening
During the first 60 days, Cavadex is not yet visibly shrinking plaque thickness on scans, but it is radically changing the plaque’s composition.
Dissolving the crystals. It aggressively targets and dissolves volatile, razor-sharp cholesterol crystals on the plaque surface and inside the necrotic core.
Thickening the fibrous cap. As inflammatory triggers are removed, local inflammation drops, allowing smooth muscle cells to build a thicker, tougher fibrous cap, making the plaque far more rupture-resistant.
Active efflux: first visible reduction
This is when actual plaque regression begins to appear on high-resolution imaging (ultrasound, CT angiogram or IVUS).
Macrophage clean-up. With toxic cholesterol crystals removed, macrophages activate via LXR pathways and become highly efficient at exporting lipids.
Volume shrinkage. Macrophages pump liquefied fat from the soft core of the plaque into passing cyclodextrin molecules. As the core drains, plaque volume decreases and the artery’s internal diameter widens.
Calcification & deep remodelling
Long-standing, calcified plaques take longer to fully remodel.
Deconstructing the matrix. Once soft lipid components are cleared, the calcified scaffolding becomes exposed. With inflammation silenced, the body can slowly reabsorb these hard structures.
Long-term patency. Over 1–2 years of sustained use, arterial walls undergo deep remodelling, restoring elasticity and locking in improved blood flow.
Why am I recalling childhood memories?
Many users report not just remembering childhood events, but re-experiencing the feelings associated with them. This is a meaningful distinction.
The hippocampus works closely with the amygdala, the brain’s emotional processing centre. Childhood memories are deeply tied to emotional and sensory states. Cavadex systematically reduces the chronic inflammatory cytokines that cross into the brain and cause low-grade neuroinflammation. As this “background static” clears, neural signalling between the hippocampus and amygdala becomes sharper.
In summary: the return of vivid childhood memories and emotions is evidence of functional neuro-restoration. Cavadex clears microvascular pathways to the brain’s memory centres, optimises neuronal membrane fluidity in the hippocampus, and lifts background neuroinflammation, allowing the brain to regain the clarity and elasticity it had decades earlier.
Interviews & real stories
Hear it from the founder and from people using Cavadex.
What you need to know: Kyle tells his story
Kyle Hodgetts was given just six months to live. With his heart failing and no options left, he made a breakthrough discovery: a simple sugar molecule called Cavadex that has now been proven to reverse heart disease by removing arterial plaque.
Now his groundbreaking treatment is saving lives, but the FDA doesn’t want you to know.
Cyclodextrin extended lifespan by almost 10% in mice
Cyclodextrin clears the vascular system and can extend lifespan.
In 2014 at the University of Texas Southwestern Medical Center, a study was conducted on the effects of cyclodextrin administered to mice. They studied the lifespan of mice treated systemically with either saline or cyclodextrin at weekly intervals, starting at 49 days of age until death. In each case, half of the males and females were given cyclodextrin and the remaining mice received only saline.
During the study the mice were graded on their neurological function. This score, which broadly measures neurological function, declines as the animal’s condition deteriorates, and there were no gender-related differences. Cyclodextrin-treated mice clearly showed higher neurological scores than mice given saline only.
All the mice given saline only had died by 98 days, whereas the majority of those receiving cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.
Want to know more?
Watch the 5-minute story, read the published papers, or get in touch.